Fig. 2 | Cellular & Molecular Immunology

Fig. 2

From: Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods

Fig. 2The alternative text for this image may have been generated using AI.

The surrogate virus neutralization test (sVNT) detects neutralizing antibodies interfering with SARS-CoV-2 S RBD binding to human ACE2. Binding of SARS-CoV-2 S RBD to human ACE2 from commercial vendor (A) and produced in-house (B). Plates were coated with ACE2 as indicated. His-tagged SARS-CoV-2 S RBD was titrated as indicated and detected with an anti-His peroxidase-labeled mAb. Representative assays performed in duplicate are presented as the mean ± SD. C Inhibition of the interaction of SARS-CoV-2 S RBD with ACE2 by the addition of sera from convalescent patients with mild (blue lines) or severe (red lines) COVID-19 and healthy controls (HC; black lines). Assay performed in duplicate; mean percentages of neutralization ± SD. D–G Inhibition of the interaction of SARS-CoV-2 S RBD with ACE2 at the serum dilutions indicated. Individual values (dots) and means (line). Shaded areas represent the mean ± 2SD of values from sera of healthy controls. *P < 0.05; ***P < 0.001, Welch’s ANOVA followed by Dunnett’s T3 multiple comparisons test. H Relative distributions of SARS-CoV-2 neutralizing serum titers determined as the dilution retaining binding reduction > mean + 2SD of HC. ***P < 0.001; Fisher’s exact test (HC vs. mild or severe) or the Chi-squared test was used to assess the trend (mild vs. severe)

Back to article page